The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50 ...
(RTTNews) - GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has approved Arexvy, Respiratory Syncytial Virus or RSVVaccine, Adjuvanted, to prevent RSV lower ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virusvaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...